AAPL341.47-1.47 (-0.43%) ▼|ABBV288.15+5.45 (+1.93%) ▲|ABT103.71-0.36 (-0.34%) ▼|ACN241.14+4.21 (+1.78%) ▲|ADBE253.99+6.90 (+2.79%) ▲|AMAT406.00-7.11 (-1.72%) ▼|AMD538.24+0.19 (+0.04%) ▲|AMGN433.94+9.00 (+2.12%) ▲|AMT183.61+0.58 (+0.32%) ▲|AMZN262.96+0.51 (+0.19%) ▲|AVGO337.39+2.80 (+0.84%) ▲|AXP319.63+3.22 (+1.02%) ▲|BA190.46-0.97 (-0.50%) ▼|BAC50.78+0.39 (+0.76%) ▲|BKNG163.70+1.10 (+0.67%) ▲|BLK1,142.30+17.70 (+1.57%) ▲|BMY60.82+1.99 (+3.37%) ▲|BNY144.18+1.74 (+1.22%) ▲|BRK-B536.80+4.57 (+0.86%) ▲|C122.00+0.31 (+0.25%) ▲|CAT720.34-5.46 (-0.75%) ▼|CL93.45+0.59 (+0.64%) ▲|CMCSA22.29+0.39 (+1.76%) ▲|COF201.22+1.39 (+0.70%) ▲|COP145.42+0.18 (+0.12%) ▲|COST998.76+3.23 (+0.32%) ▲|CRM239.54-2.92 (-1.20%) ▼|CSCO106.27-0.23 (-0.22%) ▼|CVS94.06+1.38 (+1.49%) ▲|CVX225.04+0.67 (+0.30%) ▲|DE634.66+7.66 (+1.22%) ▲|DHR224.86+0.43 (+0.19%) ▲|DIS110.84+1.25 (+1.14%) ▲|DUK120.76+1.49 (+1.25%) ▲|EMR157.21-3.33 (-2.07%) ▼|FDX296.25+2.47 (+0.84%) ▲|GD346.03+4.60 (+1.35%) ▲|GE297.69-13.59 (-4.37%) ▼|GEV902.76-5.68 (-0.63%) ▼|GILD155.22+2.15 (+1.41%) ▲|GM78.06-4.69 (-5.67%) ▼|GOOG339.69-0.47 (-0.14%) ▼|GOOGL343.48-0.70 (-0.20%) ▼|GS881.99+6.21 (+0.71%) ▲|HD314.43+4.55 (+1.47%) ▲|HON211.66+1.68 (+0.80%) ▲|IBM239.19+2.80 (+1.18%) ▲|INTC91.13-0.90 (-0.98%) ▼|INTU336.32+10.70 (+3.29%) ▲|ISRG434.26+1.08 (+0.25%) ▲|JNJ258.49+4.70 (+1.85%) ▲|JPM337.12+3.59 (+1.08%) ▲|KO93.04-0.39 (-0.41%) ▼|LIN501.30-2.15 (-0.43%) ▼|LLY1,296.65+56.31 (+4.54%) ▲|LMT552.66+4.43 (+0.81%) ▲|LOW199.19+3.27 (+1.67%) ▲|LRCX265.41-6.79 (-2.49%) ▼|MA622.69+6.29 (+1.02%) ▲|MCD245.31+2.64 (+1.09%) ▲|MDLZ63.92+0.58 (+0.92%) ▲|MDT93.99+1.22 (+1.31%) ▲|META687.80-17.65 (-2.50%) ▼|MMM170.48+8.47 (+5.23%) ▲|MO74.77+0.68 (+0.92%) ▲|MRK147.98+4.35 (+3.03%) ▲|MS180.33+1.86 (+1.04%) ▲|MSFT531.26-2.27 (-0.42%) ▼|MU904.74-0.17 (-0.02%) ▼|NEE79.09+0.92 (+1.18%) ▲|NFLX70.26+0.41 (+0.59%) ▲|NKE37.34+0.13 (+0.35%) ▲|NOW148.16+2.80 (+1.92%) ▲|NVDA216.01-1.08 (-0.50%) ▼|ORCL131.11+1.52 (+1.17%) ▲|PEP134.15+0.58 (+0.43%) ▲|PFE29.95+0.51 (+1.72%) ▲|PG158.47+0.78 (+0.49%) ▲|PLTR193.88-0.27 (-0.14%) ▼|PM200.89-0.16 (-0.08%) ▼|QCOM174.43+0.90 (+0.52%) ▲|RTX194.64+2.53 (+1.32%) ▲|SBUX99.51+1.64 (+1.67%) ▲|SCHW90.56+0.98 (+1.09%) ▲|SO90.56+1.29 (+1.45%) ▲|SPG205.26+2.77 (+1.37%) ▲|T23.58+0.38 (+1.62%) ▲|TMO682.94+3.56 (+0.52%) ▲|TMUS160.19+4.10 (+2.62%) ▲|TSLA373.33+5.27 (+1.43%) ▲|TXN279.10+2.95 (+1.07%) ▲|UBER69.07-0.89 (-1.27%) ▼|UNH416.62+9.74 (+2.39%) ▲|UNP287.88+0.87 (+0.30%) ▲|UPS98.75+1.29 (+1.32%) ▲|USB58.75+0.90 (+1.56%) ▲|V406.80+3.88 (+0.96%) ▲|VZ44.83+0.68 (+1.53%) ▲|WFC82.08+0.28 (+0.34%) ▲|WMT119.04+0.34 (+0.29%) ▲|XOM177.13-1.15 (-0.65%) ▼|AAPL341.47-1.47 (-0.43%) ▼|ABBV288.15+5.45 (+1.93%) ▲|ABT103.71-0.36 (-0.34%) ▼|ACN241.14+4.21 (+1.78%) ▲|ADBE253.99+6.90 (+2.79%) ▲|AMAT406.00-7.11 (-1.72%) ▼|AMD538.24+0.19 (+0.04%) ▲|AMGN433.94+9.00 (+2.12%) ▲|AMT183.61+0.58 (+0.32%) ▲|AMZN262.96+0.51 (+0.19%) ▲|AVGO337.39+2.80 (+0.84%) ▲|AXP319.63+3.22 (+1.02%) ▲|BA190.46-0.97 (-0.50%) ▼|BAC50.78+0.39 (+0.76%) ▲|BKNG163.70+1.10 (+0.67%) ▲|BLK1,142.30+17.70 (+1.57%) ▲|BMY60.82+1.99 (+3.37%) ▲|BNY144.18+1.74 (+1.22%) ▲|BRK-B536.80+4.57 (+0.86%) ▲|C122.00+0.31 (+0.25%) ▲|CAT720.34-5.46 (-0.75%) ▼|CL93.45+0.59 (+0.64%) ▲|CMCSA22.29+0.39 (+1.76%) ▲|COF201.22+1.39 (+0.70%) ▲|COP145.42+0.18 (+0.12%) ▲|COST998.76+3.23 (+0.32%) ▲|CRM239.54-2.92 (-1.20%) ▼|CSCO106.27-0.23 (-0.22%) ▼|CVS94.06+1.38 (+1.49%) ▲|CVX225.04+0.67 (+0.30%) ▲|DE634.66+7.66 (+1.22%) ▲|DHR224.86+0.43 (+0.19%) ▲|DIS110.84+1.25 (+1.14%) ▲|DUK120.76+1.49 (+1.25%) ▲|EMR157.21-3.33 (-2.07%) ▼|FDX296.25+2.47 (+0.84%) ▲|GD346.03+4.60 (+1.35%) ▲|GE297.69-13.59 (-4.37%) ▼|GEV902.76-5.68 (-0.63%) ▼|GILD155.22+2.15 (+1.41%) ▲|GM78.06-4.69 (-5.67%) ▼|GOOG339.69-0.47 (-0.14%) ▼|GOOGL343.48-0.70 (-0.20%) ▼|GS881.99+6.21 (+0.71%) ▲|HD314.43+4.55 (+1.47%) ▲|HON211.66+1.68 (+0.80%) ▲|IBM239.19+2.80 (+1.18%) ▲|INTC91.13-0.90 (-0.98%) ▼|INTU336.32+10.70 (+3.29%) ▲|ISRG434.26+1.08 (+0.25%) ▲|JNJ258.49+4.70 (+1.85%) ▲|JPM337.12+3.59 (+1.08%) ▲|KO93.04-0.39 (-0.41%) ▼|LIN501.30-2.15 (-0.43%) ▼|LLY1,296.65+56.31 (+4.54%) ▲|LMT552.66+4.43 (+0.81%) ▲|LOW199.19+3.27 (+1.67%) ▲|LRCX265.41-6.79 (-2.49%) ▼|MA622.69+6.29 (+1.02%) ▲|MCD245.31+2.64 (+1.09%) ▲|MDLZ63.92+0.58 (+0.92%) ▲|MDT93.99+1.22 (+1.31%) ▲|META687.80-17.65 (-2.50%) ▼|MMM170.48+8.47 (+5.23%) ▲|MO74.77+0.68 (+0.92%) ▲|MRK147.98+4.35 (+3.03%) ▲|MS180.33+1.86 (+1.04%) ▲|MSFT531.26-2.27 (-0.42%) ▼|MU904.74-0.17 (-0.02%) ▼|NEE79.09+0.92 (+1.18%) ▲|NFLX70.26+0.41 (+0.59%) ▲|NKE37.34+0.13 (+0.35%) ▲|NOW148.16+2.80 (+1.92%) ▲|NVDA216.01-1.08 (-0.50%) ▼|ORCL131.11+1.52 (+1.17%) ▲|PEP134.15+0.58 (+0.43%) ▲|PFE29.95+0.51 (+1.72%) ▲|PG158.47+0.78 (+0.49%) ▲|PLTR193.88-0.27 (-0.14%) ▼|PM200.89-0.16 (-0.08%) ▼|QCOM174.43+0.90 (+0.52%) ▲|RTX194.64+2.53 (+1.32%) ▲|SBUX99.51+1.64 (+1.67%) ▲|SCHW90.56+0.98 (+1.09%) ▲|SO90.56+1.29 (+1.45%) ▲|SPG205.26+2.77 (+1.37%) ▲|T23.58+0.38 (+1.62%) ▲|TMO682.94+3.56 (+0.52%) ▲|TMUS160.19+4.10 (+2.62%) ▲|TSLA373.33+5.27 (+1.43%) ▲|TXN279.10+2.95 (+1.07%) ▲|UBER69.07-0.89 (-1.27%) ▼|UNH416.62+9.74 (+2.39%) ▲|UNP287.88+0.87 (+0.30%) ▲|UPS98.75+1.29 (+1.32%) ▲|USB58.75+0.90 (+1.56%) ▲|V406.80+3.88 (+0.96%) ▲|VZ44.83+0.68 (+1.53%) ▲|WFC82.08+0.28 (+0.34%) ▲|WMT119.04+0.34 (+0.29%) ▲|XOM177.13-1.15 (-0.65%) ▼|
13.5 C
New York
Tuesday, October 20, 2026

Tag: clinical trial

newssourceFORcompanycontentinformation1releasesmarket

Late-Breaking Clinical Trial Results Announced at VIVA 2026

LAS VEGAS, Oct. 14, 2026 /PRNewswire/ -- The VIVA Foundation, a not-for-profit organization dedicated to advancing the field of vascular medicine and intervention through...

Florida Cancer Specialists & Research Institute Contributes to Two Significant FDA Approvals Advancing Breast and Pancreatic Cancer Care

FCS Clinical Research Continues to Pave the Way for Breakthrough TreatmentsFORT MYERS, Fla., Oct. 14, 2026 /PRNewswire/ -- Florida Cancer Specialists & Research Institute,...

Likang Life Sciences to Showcase Advances in Personalized Cancer Immunotherapy at Abu Dhabi Future Health Summit 2026

BEIJING, Oct. 14, 2026 /PRNewswire/ -- Likang Life Sciences will serve as a sponsor and exhibitor at the Abu Dhabi Future Health Summit 2026,...

Likang Life Sciences to Showcase Advances in Personalized Cancer Immunotherapy at Abu Dhabi Future Health Summit 2026

BEIJING, Oct. 14, 2026 /PRNewswire/ -- Likang Life Sciences will serve as a sponsor and exhibitor at the Abu Dhabi Future Health Summit 2026,...

Pompe Disease Market Set for Expansion During the Forecast Period (2026-2036) as Growth is Fueled by Next-Generation ERTs, Newborn Screening, and Pipeline Innovation |...

The Pompe disease market is estimated to change significantly during the forecast period (2026–2036), owing to the launch of novel therapies including MZE001 (S-606001;...

TuHURA Biosciences Receives New U.S. Patent Broadening Coverage for its VISTA Inhibitor, TBS-2025

Patent extends coverage to include bispecific/multi-specific antibodies across all classes of human antibodiesTAMPA, Fla., Oct. 13, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"...

ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention

SHANGHAI, Oct. 13, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has granted...

ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention

SHANGHAI, Oct. 12, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has granted...

ArkBio Announces FDA Clearance to Initiate Phase II Trial of AK0406 for Influenza Prevention

SHANGHAI, Oct. 13, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that the U.S. Food and Drug Administration (FDA) has granted...

Racura Oncology Cleared to Escalate RC220 to 100 mg/m2 in Phase 1 HARNESS-1 Trial in EGFR-Mutant Non-Small Cell Lung Cancer

The HARNESS-1 Safety Review Committee identified no dose-limiting toxicities or treatment-related safety concerns in either Cohort 1 patient during the safety observation period and...

Foresee Pharmaceuticals Announces China NMPA Approval of CAMCEVI® 42 mg for the Treatment of Advanced Prostate Cancer; Changchun GeneScience Pharmaceutical will Commercialize in China

TAIPEI, Oct. 12, 2026 /PRNewswire/ -- Foresee Pharmaceuticals (TPEx: 6576), ("Foresee") today announced that it was notified by its licensing partner, Changchun GeneScience Pharmaceutical...

Sebela Pharmaceuticals to Present Positive Phase 3 Tegoprazan Data in Non-Erosive Reflux Disease (NERD) at the American College of Gastroenterology (ACG) 2026 Meeting

Key Highlights:Tegoprazan is the first and only P-CAB reported to demonstrate clinical improvement in both hallmark symptoms of NERD, heartburn and regurgitation, in a...

Blood Cancer United Presents Inaugural Breakthrough Voice and Breakthrough Rising Leader Awards at First-Ever Night of Champions

Dr. Siddhartha Mukherjee and Charlotte Nathanson honored during Blood Cancer United's Breakthroughs Summit in New York CityNEW YORK, Oct. 9, 2026 /PRNewswire/ -- Blood Cancer...

New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis

Phase 3 data presented at Fall Clinical Dermatology show high, sustained response rates in adults and adolescents, with nearly three-quarters achieving clear or almost...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsClinical trial

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers